Patients Admitted With Sepsis and Gastrointestinal Bleeding, Affected by Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Exhibit Worse Clinical Outcomes

被引：0
|
作者：
Oum, Muhamad [1 ]
Albuni, Mhd Kutaiba [2 ]
Sawaf, Bisher [3 ]
Aloum, Khalid [4 ]
Sekhon, Sandeep [1 ]
机构：
[1] St Agnes Med Ctr, Fresno, CA USA
[2] TriHlth, Ad Dawhah, Qatar
[3] Univ Toledo, Hlth Sci Campus, Toledo, OH USA
[4] St Barnabas Hosp, Bronx, NY USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001037400.99816.39
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S2008
引用
收藏
页码：S1437 / S1437
页数：1
相关论文
共 50 条
  • [1] CLINICAL OUTCOMES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE PATIENTS ADMITTED WITH NON-VARICEAL GASTROINTESTINAL BLEEDING
    Rahima, Kenan
    Hijazi, Mohamad
    Albuni, Mhd Kutaiba
    Sawaf, Bisher
    Aboursheid, Tarek
    Ikpeze, Tochukwu
    GASTROENTEROLOGY, 2024, 166 (05) : S473 - S474
  • [2] CHARACTERISTICS AND CLINICAL OUTCOMES IN PATIENTS WITH CIRRHOSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN SWEDEN
    Shang, Ying
    Zhang, Xiao
    Fernandes, Gail
    Melaragno, Matthew
    Engel, Samuel
    Vessby, Johan
    Ekstedt, Mattias
    Hagstrom, Hannes
    HEPATOLOGY, 2024, 80 : S821 - S822
  • [3] Evolutionary aspects of metabolic dysfunction-associated steatotic liver disease (MASLD)
    Geier, Andreas
    Schiffels, Stephan
    Krawczyk, Marcin
    GASTROENTEROLOGIE, 2025,
  • [4] Evaluation of a Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Clinical Pharmacy Service
    Sallam, Sandy
    Ahmed, Aijaz
    Gu, Xin
    DIABETES, 2024, 73
  • [5] PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND SEVERE FIBROSIS HAVE WORSE EXECUTIVE FUNCTION PERFORMANCE
    Weinstein, Ali
    de Avila, Leyla
    Lam, Brian
    Stepanova, Maria
    Price, Jillian
    Escheik, Carey
    Gerber, Lynn
    Younossi, Zobair
    HEPATOLOGY, 2024, 80 : S827 - S828
  • [6] Evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) terminology in different clinical settings
    Iruzubieta, Paula
    Santos-Laso, Alvaro
    Arias-Loste, Maria Teresa
    Calleja, Jose Luis
    Crespo, Javier
    JOURNAL OF HEPATOLOGY, 2024, 80 (03) : e121 - e123
  • [7] Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Liu, Huan
    Yerevanian, Armen
    Westerhoff, Maria
    Hastings, Margaret H.
    Guerra, Justin Ralph Baldovino
    Zhao, Meng
    Svensson, Katrin J.
    Cai, Bishuang
    Soukas, Alexander A.
    Rosenzweig, Anthony
    DIABETES, 2024, 73 (02) : 260 - 279
  • [8] Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
    Iturbe-Rey, Santiago
    Maccali, Claudia
    Arrese, Marco
    Aspichueta, Patricia
    Oliveira, Claudia P.
    Castro, Rui E.
    Lapitz, Ainhoa
    Izquierdo-Sanchez, Laura
    Bujanda, Luis
    Perugorria, Maria J.
    Banales, Jesus M.
    Rodrigues, Pedro M.
    ATHEROSCLEROSIS, 2025, 400
  • [9] Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine MASLD
    Stefan, Norbert
    Targher, Giovanni
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2025, : 226 - 227
  • [10] Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
    Kasprzak-Drozd, Kamila
    Nizinski, Przemyslaw
    Kasprzak, Paulina
    Kondracka, Adrianna
    Oniszczuk, Tomasz
    Rusinek, Agata
    Oniszczuk, Anna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
12345